uniQure (NASDAQ:QURE) Price Target Raised to $32.00

uniQure (NASDAQ:QURE) had its price target boosted by Stifel Nicolaus from $12.00 to $32.00 in a research report report published on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on the stock. Royal Bank of Canada upped their price objective on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th. Leerink Partners increased their target price on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.13.

uniQure Trading Down 4.3 %

NASDAQ:QURE opened at $15.76 on Monday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The firm has a 50-day moving average of $7.70 and a 200-day moving average of $6.61. The company has a market cap of $768.19 million, a PE ratio of -3.18 and a beta of 0.89. uniQure has a one year low of $3.73 and a one year high of $17.71.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. As a group, equities research analysts expect that uniQure will post -3.82 EPS for the current fiscal year.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.74% of the stock is currently owned by corporate insiders.

Institutional Trading of uniQure

A number of institutional investors have recently modified their holdings of QURE. RTW Investments LP purchased a new stake in shares of uniQure during the 3rd quarter valued at approximately $49,000. China Universal Asset Management Co. Ltd. lifted its stake in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares in the last quarter. Atria Investments Inc purchased a new stake in uniQure in the 3rd quarter worth approximately $53,000. Quarry LP purchased a new stake in uniQure in the 3rd quarter worth approximately $58,000. Finally, Vanguard Personalized Indexing Management LLC lifted its stake in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.